Immune therapy for newly diagnosed multiple myeloma before stem cell transplant
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a type of immune therapy called bispecific T-cell redirectors combined with standard medicines for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if this treatment helps control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have newly diagnosed multiple myeloma that meets standard diagnostic criteria.
- You must be healthy enough to qualify for high-dose chemotherapy and a stem cell transplant.
- You must be able to care for yourself (ECOG score 0 to 2).
- You must have adequate organ function, including blood counts, kidney function, and liver tests.
- You must not have had any other cancer that could come back or require treatment now.
- You must agree to use effective birth control during the study and for a period after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment for people with newly diagnosed multiple myeloma that has not been treated before. It looks at whether adding a targeted therapy to standard treatment helps control the disease better.
This trial tests a drug that helps your immune system target and kill myeloma cells after a stem cell transplant. It is for people with newly diagnosed multiple myeloma who still have minimal residual disease (small amounts of cancer) after their first transplant.
This early-phase study tests how safe and effective several treatment approaches are for people with multiple myeloma who have already had other treatments. Depending on your myeloma features and prior care, a study drug combination may be offered to try to control the disease.
This trial tests new antibody treatments for multiple myeloma, given alone or with other drugs. It aims to see if they can control the disease and what side effects might occur.
This study tests a combination of four cancer-fighting drugs (isatuximab, iberdomide, bortezomib, and dexamethasone) followed by a stem cell transplant for people newly diagnosed with multiple myeloma. The goal is to see if this approach can help patients live longer and control their disease better.
This trial tests different dosing schedules of daratumumab to find a more cost-effective option for patients with multiple myeloma who have already had a stem cell transplant and achieved at least a partial response. It aims to see if a lower dose can work just as well.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.